Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Intraosseous malignant peripheral nerve sheath tumor of the sacrum in a patient with neurofibromatosis type I.

Davila A, Conrad EU, Ayala GE, Beckmann NM.

Radiol Case Rep. 2019 May 13;14(7):880-884. doi: 10.1016/j.radcr.2019.05.003. eCollection 2019 Jul.

PMID:
31193182
2.

Moving Beyond Gleason Scoring.

Miles B, Ittmann M, Wheeler T, Sayeeduddin M, Cubilla A, Rowley D, Bu P, Ding Y, Gao Y, Lee M, Ayala GE.

Arch Pathol Lab Med. 2019 May;143(5):565-570. doi: 10.5858/arpa.2018-0242-RA. Epub 2019 Mar 13.

PMID:
30865488
3.

Innervating Prostate Cancer.

Chen D, Ayala GE.

N Engl J Med. 2018 Feb 15;378(7):675-677. doi: 10.1056/NEJMcibr1714003. No abstract available.

PMID:
29443663
4.

Cellular interactions of the phosphorylated form of AKT in prostate cancer.

Hammerich KH, Frolov A, Li R, Ittmann M, Ayala GE.

Hum Pathol. 2017 May;63:98-109. doi: 10.1016/j.humpath.2017.02.014. Epub 2017 Mar 11.

PMID:
28300578
5.

Neuronal Trans-Differentiation in Prostate Cancer Cells.

Farach A, Ding Y, Lee M, Creighton C, Delk NA, Ittmann M, Miles B, Rowley D, Farach-Carson MC, Ayala GE.

Prostate. 2016 Oct;76(14):1312-25. doi: 10.1002/pros.23221. Epub 2016 Jul 12.

6.

Recruitment of CD34(+) fibroblasts in tumor-associated reactive stroma: the reactive microvasculature hypothesis.

San Martin R, Barron DA, Tuxhorn JA, Ressler SJ, Hayward SW, Shen X, Laucirica R, Wheeler TM, Gutierrez C, Ayala GE, Ittmann M, Rowley DR.

Am J Pathol. 2014 Jun;184(6):1860-70. doi: 10.1016/j.ajpath.2014.02.021. Epub 2014 Apr 5.

7.

FGFR1 is essential for prostate cancer progression and metastasis.

Yang F, Zhang Y, Ressler SJ, Ittmann MM, Ayala GE, Dang TD, Wang F, Rowley DR.

Cancer Res. 2013 Jun 15;73(12):3716-24. doi: 10.1158/0008-5472.CAN-12-3274. Epub 2013 Apr 10.

8.

GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy.

Sonpavde G, Thompson TC, Jain RK, Ayala GE, Kurosaka S, Edamura K, Tabata K, Ren C, Goltsov AA, Mims MP, Hayes TG, Ittmann MM, Wheeler TM, Gee A, Miles BJ, Kadmon D.

Clin Cancer Res. 2011 Nov 15;17(22):7174-82. doi: 10.1158/1078-0432.CCR-11-1899. Epub 2011 Sep 20.

9.

Neurogenesis in colorectal cancer is a marker of aggressive tumor behavior and poor outcomes.

Albo D, Akay CL, Marshall CL, Wilks JA, Verstovsek G, Liu H, Agarwal N, Berger DH, Ayala GE.

Cancer. 2011 Nov 1;117(21):4834-45. doi: 10.1002/cncr.26117. Epub 2011 Apr 8.

10.

Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens.

Ayala GE, Muezzinoglu B, Hammerich KH, Frolov A, Liu H, Scardino PT, Li R, Sayeeduddin M, Ittmann MM, Kadmon D, Miles BJ, Wheeler TM, Rowley DR.

Am J Pathol. 2011 Jan;178(1):79-87. doi: 10.1016/j.ajpath.2010.09.042. Epub 2010 Dec 23.

11.

TGF-β1 induces an age-dependent inflammation of nerve ganglia and fibroplasia in the prostate gland stroma of a novel transgenic mouse.

Barron DA, Strand DW, Ressler SJ, Dang TD, Hayward SW, Yang F, Ayala GE, Ittmann M, Rowley DR.

PLoS One. 2010 Oct 29;5(10):e13751. doi: 10.1371/journal.pone.0013751.

13.

The role of transforming growth factor-beta-mediated tumor-stroma interactions in prostate cancer progression: an integrative approach.

Basanta D, Strand DW, Lukner RB, Franco OE, Cliffel DE, Ayala GE, Hayward SW, Anderson AR.

Cancer Res. 2009 Sep 1;69(17):7111-20. doi: 10.1158/0008-5472.CAN-08-3957. Epub 2009 Aug 25.

14.

Cytoplasmic accumulation of glycogen synthase kinase-3beta is associated with aggressive clinicopathological features in human prostate cancer.

Li R, Erdamar S, Dai H, Sayeeduddin M, Frolov A, Wheeler TM, Ayala GE.

Anticancer Res. 2009 Jun;29(6):2077-81.

15.

Prognostic value of Akt-1 in human prostate cancer: a computerized quantitative assessment with quantum dot technology.

Li R, Dai H, Wheeler TM, Sayeeduddin M, Scardino PT, Frolov A, Ayala GE.

Clin Cancer Res. 2009 May 15;15(10):3568-73. doi: 10.1158/1078-0432.CCR-08-0826. Epub 2009 May 5.

16.

Cancer-related axonogenesis and neurogenesis in prostate cancer.

Ayala GE, Dai H, Powell M, Li R, Ding Y, Wheeler TM, Shine D, Kadmon D, Thompson T, Miles BJ, Ittmann MM, Rowley D.

Clin Cancer Res. 2008 Dec 1;14(23):7593-603. doi: 10.1158/1078-0432.CCR-08-1164.

17.

Application of immunohistochemistry to the genitourinary system (prostate, urinary bladder, testis, and kidney).

Hammerich KH, Ayala GE, Wheeler TM.

Arch Pathol Lab Med. 2008 Mar;132(3):432-40. doi: 10.1043/1543-2165(2008)132[432:AOITTG]2.0.CO;2. Review. Erratum in: Arch Pathol Lab Med.2008 May;132(5):730. Ayala, Gustavo A [corrected to Ayala, Gustavo E].

PMID:
18318585
18.

Malignant advanced granulosa cell tumor of the adult testis: case report and review of the literature.

Hammerich KH, Hille S, Ayala GE, Wheeler TM, Engers R, Ackermann R, Mueller-Mattheis V.

Hum Pathol. 2008 May;39(5):701-9. doi: 10.1016/j.humpath.2007.09.015. Epub 2008 Mar 4. Review.

PMID:
18304605
19.

Reprint of: Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy.

Yanagisawa N, Li R, Rowley D, Liu H, Kadmon D, Miles BJ, Wheeler TM, Ayala GE.

Hum Pathol. 2008 Feb;39(2):282-91. doi: 10.1016/j.humpath.2007.04.025.

PMID:
18206496
20.

Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition.

Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, Wang F, Ayala GE, Peterson LE, Ittmann M, Spencer DM.

Cancer Cell. 2007 Dec;12(6):559-71.

21.

Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy.

Yanagisawa N, Li R, Rowley D, Liu H, Kadmon D, Miles BJ, Wheeler TM, Ayala GE.

Hum Pathol. 2007 Nov;38(11):1611-20. Epub 2007 Sep 14.

PMID:
17868773
22.

Angiocidin inhibitory peptides decrease tumor burden in a murine colon cancer model.

Liebig C, Agarwal N, Ayala GE, Verstovsek G, Tuszynski GP, Albo D.

J Surg Res. 2007 Oct;142(2):320-6. Epub 2007 Aug 23.

PMID:
17719063
23.

Forkhead protein FKHR and its phosphorylated form p-FKHR in human prostate cancer.

Li R, Erdamar S, Dai H, Wheeler TM, Frolov A, Scardino PT, Thompson TC, Ayala GE.

Hum Pathol. 2007 Oct;38(10):1501-7. Epub 2007 Jun 26.

24.

Improved prediction of prostate cancer recurrence through systems pathology.

Cordon-Cardo C, Kotsianti A, Verbel DA, Teverovskiy M, Capodieci P, Hamann S, Jeffers Y, Clayton M, Elkhettabi F, Khan FM, Sapir M, Bayer-Zubek V, Vengrenyuk Y, Fogarsi S, Saidi O, Reuter VE, Scher HI, Kattan MW, Bianco FJ, Wheeler TM, Ayala GE, Scardino PT, Donovan MJ.

J Clin Invest. 2007 Jul;117(7):1876-83.

25.

Enhanced survival in perineural invasion of pancreatic cancer: an in vitro approach.

Dai H, Li R, Wheeler T, Ozen M, Ittmann M, Anderson M, Wang Y, Rowley D, Younes M, Ayala GE.

Hum Pathol. 2007 Feb;38(2):299-307. Epub 2006 Nov 13.

PMID:
17097719
26.

Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer.

Agoulnik IU, Vaid A, Nakka M, Alvarado M, Bingman WE 3rd, Erdem H, Frolov A, Smith CL, Ayala GE, Ittmann MM, Weigel NL.

Cancer Res. 2006 Nov 1;66(21):10594-602.

27.

Stromal antiapoptotic paracrine loop in perineural invasion of prostatic carcinoma.

Ayala GE, Dai H, Tahir SA, Li R, Timme T, Ittmann M, Frolov A, Wheeler TM, Rowley D, Thompson TC.

Cancer Res. 2006 May 15;66(10):5159-64.

28.

Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue.

Shen SS, Smith CL, Hsieh JT, Yu J, Kim IY, Jian W, Sonpavde G, Ayala GE, Younes M, Lerner SP.

Cancer. 2006 Jun 15;106(12):2610-6.

29.

Biological correlates of p27 compartmental expression in prostate cancer.

Li R, Wheeler TM, Dai H, Sayeeduddin M, Scardino PT, Frolov A, Ayala GE.

J Urol. 2006 Feb;175(2):528-32.

PMID:
16406988
30.

Bystin in perineural invasion of prostate cancer.

Ayala GE, Dai H, Li R, Ittmann M, Thompson TC, Rowley D, Wheeler TM.

Prostate. 2006 Feb 15;66(3):266-72.

PMID:
16245277
31.

Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer.

Matsumoto K, Shariat SF, Ayala GE, Rauen KA, Lerner SP.

Urology. 2005 Aug;66(2):441-6.

PMID:
16040097
32.

Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate.

Knudsen BS, Lucas JM, Fazli L, Hawley S, Falcon S, Coleman IM, Martin DB, Xu C, True LD, Gleave ME, Nelson PS, Ayala GE.

Am J Pathol. 2005 Jul;167(1):255-66.

33.

Neuroanatomy of the normal prostate.

Powell MS, Li R, Dai H, Sayeeduddin M, Wheeler TM, Ayala GE.

Prostate. 2005 Sep 15;65(1):52-7.

PMID:
15806576
34.

Transforming growth factor-beta1 induced myofibroblasts regulate LNCaP cell death.

Singh H, Dang TD, Ayala GE, Rowley DR.

J Urol. 2004 Dec;172(6 Pt 1):2421-5.

PMID:
15538284
35.

Growth and survival mechanisms associated with perineural invasion in prostate cancer.

Ayala GE, Dai H, Ittmann M, Li R, Powell M, Frolov A, Wheeler TM, Thompson TC, Rowley D.

Cancer Res. 2004 Sep 1;64(17):6082-90.

36.

Decreased stromal expression and increased epithelial expression of WFDC1/ps20 in prostate cancer is associated with reduced recurrence-free survival.

McAlhany SJ, Ayala GE, Frolov A, Ressler SJ, Wheeler TM, Watson JE, Collins C, Rowley DR.

Prostate. 2004 Oct 1;61(2):182-91.

PMID:
15305341
37.

p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.

Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF, Lerner SP.

J Clin Oncol. 2004 Mar 15;22(6):1014-24. Epub 2004 Feb 23.

PMID:
14981102
38.

Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder.

Shariat SF, Matsumoto K, Kim J, Ayala GE, Zhou JH, Jian W, Benedict WF, Lerner S.

J Urol. 2003 Sep;170(3):985-9.

PMID:
12913755
39.

Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder.

Shariat SF, Kim J, Raptidis G, Ayala GE, Lerner SP.

Urology. 2003 Jun;61(6):1140-5.

PMID:
12809883
40.

Repressors of androgen and progesterone receptor action.

Agoulnik IU, Krause WC, Bingman WE 3rd, Rahman HT, Amrikachi M, Ayala GE, Weigel NL.

J Biol Chem. 2003 Aug 15;278(33):31136-48. Epub 2003 May 27.

41.

Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model.

Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, Maddison LA, Foster BA, Greenberg NM.

Prostate. 2003 May 15;55(3):219-37.

PMID:
12692788
42.

Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder.

Shariat SF, Kim JH, Ayala GE, Kho K, Wheeler TM, Lerner SP.

J Urol. 2003 Mar;169(3):938-42.

PMID:
12576817
43.

Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling.

Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR.

Clin Cancer Res. 2002 Sep;8(9):2912-23.

44.

Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model.

Tuxhorn JA, McAlhany SJ, Dang TD, Ayala GE, Rowley DR.

Cancer Res. 2002 Jun 1;62(11):3298-307.

45.

In vitro dorsal root ganglia and human prostate cell line interaction: redefining perineural invasion in prostate cancer.

Ayala GE, Wheeler TM, Shine HD, Schmelz M, Frolov A, Chakraborty S, Rowley D.

Prostate. 2001 Nov 1;49(3):213-23.

PMID:
11746267
46.

Reactive stroma in prostate cancer progression.

Tuxhorn JA, Ayala GE, Rowley DR.

J Urol. 2001 Dec;166(6):2472-83. Review.

PMID:
11696814
47.

Low-grade fibromyxoid sarcoma: clinicopathologic case report with review of the literature.

Shidham VB, Ayala GE, Lahaniatis JE, Garcia FU.

Am J Clin Oncol. 1999 Apr;22(2):150-5. Review.

PMID:
10199449

Supplemental Content

Loading ...
Support Center